UPDATE: Goldman Sachs Lowers Johnson & Johnson's PT

According to a research report published earlier today, Goldman Sachs has lowered Johnson & Johnson's JNJ PT from $70 to $65. Goldman Sachs commented in the report, “With JNJ's earnings recovery story clouded by continued challenges in its Consumer and MD&D business, and potential competition to Zytiga and Incivo, we see the stock's premium valuation tested.” Goldman Sachs maintains its Neutral rating on Johnson & Johnson, which is currently trading at $63.34.